“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in AUD
Last close As at 24/03/2023
AUD0.06
— 0.00 (−1.69%)
Market capitalisation
AUD50m
Research: Healthcare
Respiri has announced that, along with partner Access Telehealth, it has successfully concluded a system integration of the companies’ platforms with the Michigan Children’s Hospital, the company’s first US customer. This includes Respiri’s proprietary wheezo device, application and health portal (which manages respiratory health data) along with Access Telehealth’s remote patient monitoring (RPM) platform, Remotli. Patient intake is expected to start in the coming weeks and would mark the first patient use of wheezo in the US, feedback from which is likely to set the direction for future uptake. We highlight that the market for wheezo in the US is expected to be physician led and, unlike Respiri’s domestic Australian market, is reimbursed under the relevant RPM procedural terminology codes. The US market therefore presents a significant opportunity for Respiri.
Respiri |
Wheezo to begin patient use in the US
|
Pharma and biotech |
QuickView
1 August 2022 |
Share price graph
Share details
Business description
Bull
Bear
Analysts
|
||||||||||||||||||||||||
Respiri has announced that, along with partner Access Telehealth, it has successfully concluded a system integration of the companies’ platforms with the Michigan Children’s Hospital, the company’s first US customer. This includes Respiri’s proprietary wheezo device, application and health portal (which manages respiratory health data) along with Access Telehealth’s remote patient monitoring (RPM) platform, Remotli. Patient intake is expected to start in the coming weeks and would mark the first patient use of wheezo in the US, feedback from which is likely to set the direction for future uptake. We highlight that the market for wheezo in the US is expected to be physician led and, unlike Respiri’s domestic Australian market, is reimbursed under the relevant RPM procedural terminology codes. The US market therefore presents a significant opportunity for Respiri.
Respiri’s flagship wheezo platform supports the monitoring and maintenance of irregular breathing patterns (wheeze) in asthma and chronic obstructive pulmonary disease (COPD) patients, both areas with a large patient population (50 million people are living with asthma or COPD in the US, according to the company) that currently lacks adequate tracking and monitoring. The current standard of care is an asthma control questionnaire or asthma control test, which relies on patient recall and response and is therefore prone to subjectivity. Other tests such as spirometry to test lung function are not user friendly (requiring forced breathing) and difficult to administer to children and the elderly. In contrast, the wheezo device needs to record only 30 seconds of normal breathing (with the device placed against the trachea) to provide objective physiological data (such as wheeze rate) and therefore has the potential to address a large unmet space.
The announced system integration with the Michigan Children’s Hospital covers the entire wheezo ecosystem, ranging from the device and related application to the company’s remote healthcare monitoring portal (which records data such as wheeze rates, breath recordings and other triggering factors such as pollution, pollen and medication usage). To support the integration program, Respiri has developed an application programming interface functionality, which allows its health portal to integrate with Remotli to capture key metrics such as wheeze rates, which is the key physiological parameter required for RPM reimbursement by the payors. We note that the need for the implementation of new systems has historically been a major barrier to entry for new services into hospitals and healthcare providers and this one-time investment should allow Respiri easier/faster integration with new Access-engaged healthcare customers.
We expect feedback from the first-patient access at the Michigan Children’s Hospital to lay the foundation for subsequent uptake of the product and associated services. We note that Detroit, the location of the children’s hospital, is home to over 70,000 children living with asthma and the hospital offers extensive asthma outpatient services, providing a sound launchpad for Respiri to release its device.
EDISON QUICKVIEWS ARE NORMALLY ONE-OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.
|
|
Research: Healthcare
Ahead of its FY22 results, Arovella has released its quarterly activities report, reiterating key developments and milestones achieved in the closing quarter of the financial year. While the key highlight was the signing of the manufacturing agreement with Q-Gen for its chimeric antigen receptor-invariant natural killer T (CAR-iNKT) programme ALA-101, initiation of commercial activities (with the launch of ZolpiMist in Australia) was another major milestone. Arovella also secured the US patent for Anagrelide (an under-development oral spray formulation for solid tumours), which expands on its existing patents in Europe, Japan and Australia. Additionally, Arovella announced its first ESG report, based on the World Economic Forum’s framework. The cash balance stood at A$6.1m at the end of Q422.
Get access to the very latest content matched to your personal investment style.
